11 completed, 5 recruiting, 2 terminated, 1 not yet recruiting. 6 Not applicable, 6 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 3, Recruiting 2, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 3 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Lipodystrophy, Familial Partial: new trials by email Literature Review of Lipodystrophy, Familial Partial trials Research Report on Lipodystrophy, Familial Partial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sexual Quality of Life in Female Patients With Lipodystrophy Syndromes or Turner's Syndrome: a Case-control Study Lipodystrophy Congenital Generalized, Lipodystrophy, Familial Partial | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1416 | 2026-10-01 | 2026-09-02 | |
| Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS) Genetic analysis, Biological analysis, imaging test - Polycystic Ovary Syndrome, Familial Partial Lipodystrophy | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 81 | 2026-07-21 | 2026-08-10 |
| Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy Mibavademab, Placebo - Generalized Lipodystrophy | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 28 | 2026-03-13 | 2026-09-11 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
| Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Metreleptin - Familial Partial Lipodystrophy | Phase 3 | Recruiting | Chiesi Farmaceutici S.p.A. | 24 | 2024-10-14 | 2026-07-16 |
| The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island. Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring - High Cholesterol, Lipodystrophy, Familial Partial | Completed | Centre Hospitalier Universitaire de la Réunion | 126 | 2024-05-06 | 2025-07-31 | |
| Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects Bood and urine sampling - Lipodystrophy, Dunnigan Syndrome | Not applicable | Completed | Centre Hospitalier Universitaire de la Réunion | 64 | 2023-08-14 | 2026-09-16 |
| Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2 Biopsy - Familial Partial Lipodystrophy Type 2 | Completed | University Hospital, Lille | 25 | 2022-04-19 | 2025-12-26 | |
| A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) REGN4461, Matching Placebo - Familial Partial Lipodystrophy, Metabolic Abnormalities | Phase 2 | Terminated | Regeneron Pharmaceuticals | 20 | 2022-02-28 | 2025-10-16 |
| Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan's Lipodystrophy research-specific blood sample - Lipodystrophy, Dunnigan Syndrome | Not applicable | Completed | Centre Hospitalier Universitaire de la Réunion | 150 | 2021-08-17 | 2023-10-25 |
| Low Energy Diet and Familial Partial Lipodystrophy Total Dietary Replacement - Lipodystrophy, Diabetes | Not applicable | Recruiting | Cambridge University Hospitals NHS Foundation Trust | 20 | 2020-01-16 | 2024-12-05 |
| Lipodystrophy and Fat Metabolism During Exercise Caffeine, High-carbohdyrate breakfast, 60-minutes of steady state exercise - Healthy, Lipodystrophy, Familial Partial | Not applicable | Withdrawn | University of Exeter | 2019-09-01 | 2021-08-31 | |
| Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) AKCEA-ANGPTL3-LRx - Familial Partial Lipodystrophy | Phase 2 | Completed | Akcea Therapeutics | 4 | 2018-06-15 | 2021-02-16 |
| Study of Gemcabene in Adults With FPLD 300mg Gemcabene, 600mg Gemcabene - Familial Partial Lipodystrophy, Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Elif Oral | 5 | 2018-03-13 | 2020-08-17 |
| Registry for Patients With Lipodystrophy Lipodystrophy Acquired, Lipodystrophy Congenital | Recruiting | University of Ulm | 5000 | 2017-12-16 | 2025-12-02 | |
| Familial Partial Lipodystrophy Study High fat mixed meal - Lipodystrophy, Familial Partial | Not applicable | Completed | Mayo Clinic | 12 | 2016-08-01 | 2021-11-24 |
| Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients Obeticholic Acid, Placebo - Familial Partial Lipodystrophy | Phase 2 | Completed | Abhimanyu Garg | 10 | 2016-06-01 | 2024-08-27 |
| The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy volanesorsen, Placebo - Familial Partial Lipodystrophy | Phase 2 / Phase 3 | Terminated | Akcea Therapeutics | 40 | 2015-12-28 | 2021-10-18 |
| CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Metreleptin - Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis | Phase 2 | Completed | University of Michigan | 11 | 2015-09-29 | 2020-11-24 |
| Lipodystrophy Connect Patient Registry Lipodystrophy | Completed | PatientCrossroads | 257 | 2014-01-01 | 2019-04-22 |
Lipodystrophy (8) · Diabetes Mellitus (4) · Hypertriglyceridemia (3) · Lipodystrophy, Congenital Generalized (3) · Dyslipidemias (2) · Fatty Liver (2) · Insulin Resistance (2) · Non-alcoholic Fatty Liver Disease (2) · Diabetes Mellitus, Lipoatrophic (1) · Hypercholesterolemia (1) · Hyperinsulinism (1) · Lipid Metabolism Disorders (1) · Lipodystrophy, Partial, Acquired (1) · Obesity, Morbid (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Genetic Diseases, Inborn (20) · Laminopathies (20) · Lipid Metabolism, Inborn Errors (20) · Metabolic Diseases (20) · Nutritional and Metabolic Diseases (20) · Skin Diseases (20) · Skin Diseases, Metabolic (20) · Skin and Connective Tissue Diseases (20) · Lipid Metabolism Disorders (19) · Lipodystrophy (12) · Endocrine System Diseases (7) · Glucose Metabolism Disorders (6) · Dyslipidemias (4) · Hyperlipidemias (4)
metreleptin (2) · Biological Oxygen Demand Analysis (1) · Biopsy (1) · Caffeine (1) · Genetic Testing (1) · ISIS 304801 (1) · Investigational New Drug Application (1) · gemcabene (1) · obeticholic acid (1)
Centre Hospitalier Universitaire de la Réunion (3) · Regeneron Pharmaceuticals (3) · Akcea Therapeutics (2) · Assistance Publique - Hôpitaux de Paris (2) · Abhimanyu Garg (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Chiesi Farmaceutici S.p.A. (1) · Elif Oral (1) · Mayo Clinic (1) · PatientCrossroads (1) · University Hospital, Lille (1) · University of Exeter (1) · University of Michigan (1) · University of Ulm (1)
United States (11) · France (6) · Reunion (3) · United Kingdom (3) · Brazil (2) · Germany (2) · Netherlands (2) · Russia (2) · Spain (2) · Turkey (Türkiye) (2) · Austria (1) · Belgium (1) · Canada (1) · Greece (1) · Hungary (1)
Abhimanyu Garg, MD (1) · Andrew Davenport, MSc (1) · Camille Vatier, Dr. (1) · David Araujo-Vilar, Prof. Dr. (1) · David Savage (1) · David Savage, Prof. (1) · Elif A Oral, M.D. (1) · Elif A Oral, MD (1) · Gabriele Nagel, Prof. (1) · Giovanni Ceccarini, Dr. (1) · Julia von Schnurbein, Dr. (1) · Marie-Christine Vantyghem, Prof. (1) · Martin Wabitsch, Prof. Dr. (1)
2015 (1)